Controversies in the therapy of early stage breast cancer
Controversies in the therapy of early stage breast cancer
复制标题
DOI：
10.1634/theoncologist.10-10-766
复制
发表时间：
2005-11-01
期刊：
影响因子：
5.8
通讯作者：
Gradishar, WJ
中科院分区：
文献类型：
--
作者：
Cianfrocca, M;Gradishar, WJ
乳腺癌是美国妇女中最常见的恶性肿瘤，每年诊断出超过20万例新病例。在美国，近年来，由于更广泛的筛查，导致早期发现，以及早期疾病辅助治疗的进展，乳腺癌死亡率有所下降。早期乳腺癌患者适当的辅助化疗和内分泌治疗可以提高患者的无病生存率和总生存率。因此，对淋巴结阳性和高危、淋巴结阴性乳腺癌患者进行辅助全身治疗是标准的临床实践。然而，在乳腺癌的主要系统治疗中仍然存在许多争议，在本文中进行了讨论。
Breast cancer is the most common malignancy among U.S. women, with more than 200,000 new cases diagnosed annually. In the U.S., mortality from breast cancer has declined in recent years as a result of more widespread screening, leading to earlier detection, as well as advances in the adjuvant treatment of early-stage disease. It is widely accepted that the appropriate use of adjuvant chemotherapy and endocrine therapy improves the disease-free and overall survival of patients with early-stage breast cancer. It is, therefore, standard clinical practice to administer adjuvant systemic therapy to patients with node-positive and high-risk, node-negative breast cancer. There remain, however, many controversies in the primary systemic therapy of breast cancer, which are discussed in this review.